Consilium Strategic communications

What Consilium Strategic communications does

Consilium Strategic Communications is a London-headquartered professional services firm specializing in strategic communications for the healthcare sector. Founded in 2013 and now operating as part of ICR Healthcare following its acquisition by ICR, the firm functions within a global division that comprises more than 100 advisors across the United States, Europe, and Asia and serves 200+ clients in 20+ countries. Its service portfolio spans investor relations, corporate communications and public relations, IPO and transaction advisory, branding and creative, crisis and special situations, governance and activism advisory, and event planning. Target clients are innovative healthcare companies across biotechnology, pharmaceuticals, medical technology, diagnostics and tools, healthcare information technology, and healthcare services sub-sectors.

The firm operates on a professional services revenue model with quote-based engagements and undisclosed pricing. Services are delivered through direct enterprise engagement by regional teams anchored in New York, London, and Beijing. The client roster includes large listed healthcare companies such as Abbott, Agilent, Teleflex, Supernus Pharmaceuticals, and Merit Medical alongside emerging biotech and medtech issuers such as OXB, Moonlake, OMass Therapeutics, CMR Surgical, and 4DMT. The firm has guided hundreds of healthcare companies through IPO processes and supported management teams facing complex capital markets and corporate transactions.

Strategic positioning rests on deep sector specialization and capital-markets fluency: senior practitioners drawn from Wall Street and top-tier healthcare media, paired with retained brand identity alongside Westwicke (the largest US healthcare IR agency) under ICR Healthcare. Legal entity is ICR Inc., domiciled in the United States, with Consilium operating as a wholly owned, brand-retained subsidiary focused on European and international healthcare clients.

Name

Consilium Strategic communications

Legal name

ICR Inc.

Website

https://consilium-comms.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Consilium Strategic Communications is a London-based, ICR-owned healthcare public relations and investor relations advisory firm serving biotech, pharma, medtech, diagnostics, and healthcare services clients across more than 20 countries as part of ICR Healthcare's global 100-advisor team.

Ownership category

akta.pro rank

Product category

Healthcare Strategic Communications

NAICS

Public Relations Agencies (54182), Public Relations Agencies (541820), Advertising, Public Relations, and Related Services (5418)

SIC

Communications Services, Nec (4899)

akta.pro primary industry

Healthcare & Life Sciences PR (MPAAADAD)

akta.pro secondary industries

Healthcare & Life Sciences PR (BPAFADAJ), Investor Relations (IR) & Capital Markets Communications (MPAAADAH)

Keywords

• Healthcare communications
• Investor relations advisory
• Corporate public relations
• IPO advisory services
• Crisis communications

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations

Revenue model

1. Strategic Communications and Advisory Services: Professional services revenue model providing strategic healthcare communications, investor relations, corporate PR, IPO advisory, and branding/creative services to healthcare companies across biotech, pharma, medtech, diagnostics, and healthcare services sectors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Consilium Strategic Communications is a healthcare-focused strategic communications firm providing investor relations, corporate communications and public relations, IPO and transaction advisory, branding and creative services, crisis and special situations communications, governance and shareholder advisory, and event planning. Operating as part of ICR Healthcare, the firm serves biotech, pharmaceutical, medtech, diagnostics, healthcare services, and healthcare IT clients across the US, Europe, and Asia with a team of 100+ advisors.

Product overview

Consilium Strategic Communications, acquired by ICR, is a strategic healthcare communications firm offering a comprehensive suite of advisory services. The firm provides investor relations, corporate communications and public relations, IPO and transaction advisory, branding and creative services, crisis communications, governance advisory, and event planning and management. The services are delivered by a team of over 100 advisors across the US, Europe and Asia, supporting 200+ clients in 20+ countries. The offering is a services-based model rather than a software product platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Investor Relations

Quantifiable outcome

• 200+ clients in 20+ countries
• +1 more outcomes

Named customers26 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• WestwickecoreStrategic or Co-development PartnerWestwicke, the largest healthcare investor relations agency in the US, was acquired by ICR. This acquisition expanded ICR Healthcare's capabilities in investor relations advisory services for healthcare companies, combining Westwicke's expertise with Consilium's PR capabilities to create a comprehensive healthcare communications offering.
• ICR (Investor Consensus Relations)coreStrategic or Co-development PartnerConsilium Strategic Communications was acquired by ICR and operates as part of ICR Healthcare. ICR is one of the largest independent US communications agencies, providing the platform for Consilium to deliver comprehensive, seamless communications and advisory support to healthcare clients globally.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Real Chemistry (formerly W2O Group): Large independent healthcare-focused communications and data firm offering IR, PR, and analytics to biopharma and medtech. Comparable healthcare specialization at much greater scale, posing the most significant competitive threat to mid-sized specialists like Consilium.
• FleishmanHillard: Global holding-company communications agency with a substantial healthcare practice serving pharma, biotech, and medtech. Comparable in service scope but operates as part of a much broader portfolio across industries.

Direct peers

• LifeSci Communications: Specialist healthcare PR and communications agency serving biotech, pharma, and medical device companies. Directly comparable vertical focus and mid-market positioning.
• Lazar Partners: Healthcare and life sciences communications firm providing IR and PR services to biotech and emerging pharma. Direct mid-sized competitor in the same niche with overlapping service lines and customer base.
• Westwicke Partners: Healthcare-focused investor relations advisory firm and now a sister brand under ICR Healthcare. Directly comparable offering in healthcare IR, with complementary US-centric client base relative to Consilium's UK/European book.
• Rx Communications Group: Healthcare and biopharma communications firm providing IR, PR, and corporate communications services. Comparable mid-sized specialist competing in biotech IR mandates and corporate visibility programs.
• Canale Communications: Specialist life sciences PR and communications agency serving biotech, pharma, and digital health clients. Directly comparable in target customer, vertical focus, and service mix (corporate communications, media relations, IR support).
• Tiberend Strategic Advisors: Healthcare-focused strategic communications and IR firm serving biotech and pharma. Comparable mid-sized specialist, often pitching against Consilium/ICR Healthcare for biotech IR mandates.
• Burns McClellan: Life sciences communications and investor relations firm focused on biotech and emerging pharma clients. Comparable mid-sized specialist offering IR, PR, and financial communications services.
• Argot Partners: Healthcare-specialist IR and strategic communications firm serving biotech, medtech, and pharma. Direct peer with comparable IR-heavy service model and similar growth-stage issuer client profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ConsiliumHC
• LinkedInlinkedin.com/company/icr
• Instagraminstagram.com/icrincllc
• Facebookfacebook.com/ConsiliumStrategicCommunications

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Consilium Strategic communications